Protara Therapeutics to Present at the H.C. Wainwright BioConnect Virtual Conference
04. Januar 2022 08:00 ET
|
Protara Therapeutics
NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Third Quarter 2021 Financial Results and Business Overview
04. November 2021 08:00 ET
|
Protara Therapeutics
– TARA-002 Confirmatory Large-Scale GMP Comparability Complete – – U.S. FDA Cleared the Company’s IND Application for TARA-002 in NMIBC; Company Plans to Initiate Phase 1 Clinical Trial by Year-End –...
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
25. Oktober 2021 16:45 ET
|
Protara Therapeutics
NEW YORK, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing transformative therapies for the treatment of cancer and rare diseases,...
Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
12. Oktober 2021 07:00 ET
|
Protara Therapeutics
- Company Plans to Initiate Phase 1 Study of TARA-002 by Year-End - - IND Application Included Submission of Confirmatory Large-Scale GMP Comparability Data - NEW YORK, Oct. 12, 2021 (GLOBE...
Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
17. September 2021 16:05 ET
|
Protara Therapeutics
NEW YORK, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
13. September 2021 07:00 ET
|
Protara Therapeutics
-Study found that approximately 30% of patients who are dependent on parenteral nutrition have cholestasis- -Results support significant unmet medical need in patients dependent on parenteral...
Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
07. September 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...
Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview
05. August 2021 08:00 ET
|
Protara Therapeutics
- Successfully Completed IND-Enabling Studies for TARA-002 in Patients with NMIBC; On Track to Initiate Phase 1 Trial by Year-End - - TARA-002 GMP Scale up and Comparability Ongoing and Expected to...
Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference
07. Juli 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...
Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors
10. Juni 2021 08:00 ET
|
Protara Therapeutics
NEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with...